Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene ExpressionDavid A. Jacobsohn, Michael A. Pulsipher, Sana Khan et al.|Transplantation and Cellular Therapy|2018Cited by 44
Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell DepletionTheresa Hahn, Philip L. McCarthy, Arif Alam et al.|Transplantation|2004Cited by 38
Excellent Relapse-Free and Overall Survival in Pre-HCT Next-Generation Sequencing (NGS-MRD) Negative B-ALL Patients with or without TBI-Based Conditioning: Outcome of the Observational Arm of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701 Endrad StudyHisham Abdel‐Azim, Michael A. Pulsipher, Troy C. Quigg et al.|Transplantation and Cellular Therapy|2023Cited by 5
Chronic Kidney Disease Is Common in Survivors of Pediatric Allogeneic Hematopoietic Cell Transplantation: A Pediatric Transplantation and Cellular Therapy Consortium StudyChristine Duncan, Sangeeta Hingorani, Scott Baker et al.|Transplantation and Cellular Therapy|2022Cited by 1
Skeletal Biology and Late Effects Following Allogeneic Transplantation for Pediatric Hematologic Malignancy: A Ptctc and CIBMTR Multicenter StudyChristine Duncan, K. Scott Baker, Nan Chen et al.|Transplantation and Cellular Therapy|2023Cited by 1